Brooke Delaney

Brooke Delaney


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
RMRommani Mondal
Rommani Mondal
YSYasmin Kaur Sandhu
Yasmin Kaur Sandhu
VKVallabhi M. Kamalia
Vallabhi M. Kamalia
BDBrooke Delaney
Brooke Delaney
ASAmina U Syed
Amina U Syed
Jogeshwar MukherjeeJogeshwar Mukherjee
Jogeshwar Mukherjee
High-resolution scans of immunohistochemical (IHC) stains of Alzheimer’s disease (AD) brain slices and radioligand autoradiography both provide information about the distribution of Aβ plaques and Tau, the two common proteinopathies in AD. Accurate assessment of the amount and regional location of Aβ plaques and Tau is essential to understand the progression of AD pathology. Our goal was to develop a quantitative method for the analysis of IHC–autoradiography images. Postmortem anterior cingulate (AC) and corpus callosum (CC) from AD and control (CN) subjects were IHC stained with anti-Aβ for Aβ plaques and autoradiography with [18F]flotaza and [125I]IBETA for Aβ plaques. For Tau, [124I]IPPI, a new radiotracer, was synthesized and evaluated in the AD brain. For Tau imaging, brain slices were IHC stained with anti-Tau and autoradiography using [125I]IPPI and [124I]IPPI. Annotations for Aβ plaques and Tau using QuPath for training and pixel classifiers were generated to measure the percent of the area of Aβ plaques and Tau in each slice. The binding of [124I]IPPI was observed in all AD brains with an AC/CC ratio > 10. Selectivity to Tau was shown by blocking [124I]IPPI with MK-6240. Percent positivity for Aβ plaques was 4–15%, and for Tau, it was 1.3 to 35%. All IHC Aβ plaque-positive subjects showed [18F]flotaza and [125I]IBETA binding with a positive linear correlation (r2 > 0.45). Tau-positive subjects showed [124/125I]IPPI binding with a stronger positive linear correlation (r2 > 0.80). This quantitative IHC–autoradiography approach provides an accurate measurement of Aβ plaques and Tau within and across subjects.

28 March 2025 in Brain Research
Verified
Journal Article
Open access
FKFariha Karim
Fariha Karim
ANAllyson Ngo
Allyson Ngo
TDTram B. Danh
Tram B. Danh
BDBrooke Delaney
Brooke Delaney
CLChristopher Liang
Christopher Liang
Jogeshwar MukherjeeJogeshwar Mukherjee
Jogeshwar Mukherjee
Nicotinic acetylcholinergic receptors (nAChRs), including the α4β2* subtype are involved in cognition, learning and memory and may be adversely affected in Alzheimer's disease (AD). In our efforts to consider translational use of [18F]nifene PET in AD, we report quantitative autoradiographic evaluation of α4β2* nAChRs using hippocampus-subiculum (HP-SUB) from cognitively normal (CN) and AD subjects. Brain slices were incubated in [18F]nifene for α4β2* nAChRs and adjacent sections were tested with [18F]flotaza for Aβ plaques and [125I]IPPI for tau. Anti-Aβ and anti-tau immunostaining were carried out on adjacent slices. Regions of interest were drawn and binding of [18F]nifene, [18F]flotaza and [125I]IPPI were quantified.All CN subjects exhibited significant [18F]nifene binding in the HP-SUB regions. Average [18F]nifene ratios of SUB to HP was 1.9, suggesting higher α4β2* nAChRs in the SUB versus HP regions. [18F]nifene binding did not change with aging in the female subjects, while the male subjects exhibited a weak positive correlation. There was a significant decrease in the binding of [18F]nifene in AD subjects compared to CN. Braak stage comparisons showed a decrease of [18F]nifene in stages V and VI, while [18F]flotaza and [125I]IPPI increased significantly. A negative correlation was observed between [18F]nifene vs [18F]flotaza and [18F]nifene vs [125I]IPPI across Braak stages I-VI. These findings suggest that α4β2* nAChR availability was effectively measured by [18F]nifene in the HP-SUB and was adversely affected by the presence of Aβ plaques and tau.